ArticleLeukemia research2019

Corrigendum to "Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib" [Leukemia Res. 79 (2019) 38-44].

Aaron T Gerds et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.